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Matrix metalloproteinases (MMPs) are a family of proteolytic
enzymes which are associated with tissue remodelling in both
normal and pathological processes (Harris, 1990; Page, 1991).
These enzymes, which degrade the extracellular matrix, are
thought to play an important role in conferring metastatic potential
to tumour cells and their overexpression has been correlated with
the stage of progression in many tumour types (Hewitt et al, 1991;
Davies et al, 1993; Stetler-Stevenson et al, 1993). Colorectal carci-
nomas comprise malignant epithelial cells and stroma and it is the
stromal component which may prove critical in the spread of
malignant cells to distant sites. These stromal cells express matrix
degrading enzymes more frequently than cancer cells (Heppner 
et al, 1996; Ornstein et al, 1999; Saito et al, 2000) and it has been
found that tumour derived diffusible factors such as EGF, TGF-a,
TNF-a, PDGF and IL-1b influence this expression (reviewed by
Westermarck and Kahari, 1999). 
Among the extensive MMP family (23 to date) MMP-2 is
proving to be important in the degradative process and is predom-
inantly expressed by the stromal component of tumours. Type IV
collagen, which is the specific substrate of MMP-2, is a major
constituent of the basement membrane, which is breached during
invasive cancer. The active enzyme seems to have the tightest
correlation with the malignant phenotype (Liabakk et al, 1996;
Parsons et al, 1998) and may initiate an activation cascade which
is known to exist within this enzyme family. Therefore, the control
of MMP-2, along with its interaction with its specific activator
MT-1-MMP and its specific inhibitor TIMP-2 may prove crucial in
understanding the degradative process. TIMP-2 specifically
inhibits MMP-2 in a 1:1 ratio but also contributes to its activation
when present at low levels. 
The second gelatinase (MMP-9) is differentially expressed by
the tumour, it is expressed predominantly by inflammatory cells
but can be induced by autocrine (Shimizu et al, 1996) and
paracrine (Lengyel et al, 1995) stimulation. It is known to be a
target of the active MMP-2 (Fridman et al, 1995) but is also
susceptible to activation by other proteinases (reviewed by
Birkedal-Hansen et al, 1993). 
To further understand the contribution of tumour and stromal
cells to the invasive process we analysed MMPs, their inhibitors
and activators in systems of increasing complexity. MMP expres-
sion was examined in 2 colorectal cancer cell lines, and it was
determined whether this profile was changed under the influence
of stromal cells both in vitro and in vivo. The competitive-based
RT-PCR assay described by Wells et al (1996) was the technique
used to quantify the MMPs relative to the housekeeping gene
GAPDH. This technique relies on a competition reaction in which
a synthetic standard cDNA is co-amplified with the target cDNA
in the same PCR reaction. The standard multi-competitor cDNA
contains priming sites for human matrix metalloproteinases and
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Summary The matrix metalloproteinases, MMP-2 and MMP-9, are capable of degrading components of the basement membrane, a vital
barrier breached during the progression of colorectal cancer. The regulation of MMP-2 activation and subsequent targets is vital to
understanding the metastatic process. MMP-2 was not expressed by colorectal cancer cells (C170 and C170HM2) in vitro but by stromal
fibroblasts (46BR.1GI). There was induction of this MMP upon transwell co-cultivation of the colon cancer cells with the fibroblasts but in vivo
growth did not lead to a similar increase in the metastatic tumour cells (C170HM2), MMP-2 again being attributed to the stromal cells. MMP-2
mRNA was overexpressed in human colorectal tumours compared to normal colorectal tissue, which correlated with Dukes’ stage and
immunolocalized to the stromal compartment of the tumour tissue. The active form of the MMP-2 enzyme was also present in the colorectal
tumour tissue (7/8) but essentially absent in all normal colon samples examined (1/8). MMP-2 activation was not related to an increase in 
MT-1-MMP mRNA or a decrease in the specific inhibitor TIMP-2 in human tissue. There was however an increase in MMP-2/TIMP-2 ratio in
tumour compared to normal. MMP-9, a target of active MMP-2, was present in the metastatic cell line but expression was down-regulated
in the tumour cells in vivo, gelatin analysis revealed that MMP-9 was almost entirely attributable to the murine host, confirmed by PCR. There
was no increase in mRNA for MMP-9 or its specific inhibitor TIMP-1 in colorectal tumour tissue compared to normal, MMP-9 protein localized
to the inflammatory infiltrate. Fibroblast cells may provide malignant epithelial cells with a ready source of enzyme which is crucial to the
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GAPDH. MMP and TIMP expression was also measured in both
normal and tumour colorectal tissue. 
MATERIALS AND METHODS 
Cells and culture conditions 
2 colorectal cancer cell lines were utilized in this study; C170 was
established from a poorly differentiated human colorectal primary
tumour (Durrant et al, 1986). C170HM2 is a metastatic derivative
of C170 which was established by selecting liver-invading
tumours (Watson et al, 1993). The human fibroblast cell line
46BR.1GI (ECACC, UK) was used as an example of a stromal cell
type. Cells were cultured in RPMI 1640 medium (Sigma, Poole,
Dorset) containing 10% heat inactivated fetal calf serum (Sigma),
at 37˚C in a humidified atmosphere of 5% CO2. Cells to be grown
as subcutaneous tumours were injected at a concentration of 2 ´
106 in 200 ml 0.5% NaCl into the flank of MF1 nude mice, bred
within the Cancer Studies Unit, University of Nottingham. After
15–20 days growth the mice were sacrificed and the resultant
tumour was dissected free and fixed as described below. To initiate
liver-invasive growth, C170HM2 cells were injected into the peri-
toneal cavity (106 cells in 1 ml 0.5% NaCl), as previously
described by Watson et al (1993), after 40 days the mice were
sacrificed and liver-invasive tumours dissected free from the
normal liver parenchyma. Following excision and dissection,
tumours were snap frozen for mRNA extraction or cork mounted
and snap frozen in isopentane pre-cooled in liquid nitrogen, for
SDS PAGE gelatin zymography and immunohistochemistry
(described below). All animal work was carried out in accordance
with UKCCCR guidelines. 
Co-cultivation assay 
46BR.1GI was co-cultivated in serum free medium (1:1 HAMS
F12:RPMI 1640) with the colorectal cancer cell lines C170 and
C170HM2 in transwell plates (Costar, UK) separated by 3 mm
porous filters. All assays were conducted for 72 hours, at which
point each cell type was harvested and mRNA extracted. In addi-
tion to transwell co-cultivation a system where colorectal cells and
fibroblasts were in cell–cell contact was set up. Conditioned media
from each assay was subjected to gelatin zymography. 
Clinical samples 
Fresh tissue samples were collected from patients undergoing
routine resection for colorectal cancer in the Section of Surgery at
the Queens Medical Centre, Nottingham. All samples underwent
routine histological examination and the tumours were classified
independently by a pathologist according to Dukes’ stage. There
were 4 Dukes’ stage B and 4 Dukes’ stage C tumours. Control
normal colorectal tissue (n = 8) was obtained from sites remote
from the tumour. 
mRNA extraction 
For preparation of mRNA the tissue samples were finely ground in
liquid nitrogen using a pre-cooled pestle and mortar. The tissue
was then transferred to extraction buffer and homogenized for
30 seconds. The mRNA was extracted from cell line pellets and
tissue samples using guanidium thiocyanate and purified using
oligo(dT)-cellulose chromatography (Amersham Pharmacia, UK).
Double-stranded cDNA was synthesized from mRNA using the
Riboclone® cDNA synthesis system MMLV (H
–) (Promega, UK). 
RT-PCR 
The double-stranded cellular cDNA was subjected to 35 cycles of
PCR amplification in a Hybaid thermal cycler. Each cycle
consisted of 30 s denaturation at 95˚C, 30 s annealing at 57˚C and
2 min of primer extension at 72˚C. Each 50 ml reaction contained
3.5 mM MgCl2, 50 mM Tris HCl, pH 9.1, 200 mM each dNTP,
50 pmol each primer and 1 unit Taq DNA polymerase (Helena
Biosciences, UK). An initial RT-PCR screen was performed with a
wide range of MMPs (MMP -1, -2, -7, -9, MT-1-MMP, and -2) and
TIMPs -1 and -2. All human primers were designed and kindly
donated by British Biotech Ltd (Oxford, UK). The mRNA
levels for MMP-2, MMP-9, MT-1-MMP, TIMP-1 and TIMP-2
were then measured by quantitative PCR as described by 
Wells et al (1996). MMP-9 was also examined from in vivo
tumours using the murine specific primers 5¢-GGGCTTAGAT-
CATTCCAGCG-3¢ and 5¢-CCGTGGGAGGTATAGTGGGA-3¢. 
Quantitative RT-PCR 
Quantitation was achieved using a standard multi-competitor
cDNA construct (PQH1 or PQH6) kindly donated by British
Biotech Ltd (Oxford, UK). 3-fold serial dilutions of the standard
competitor starting at 200 pg were combined with a constant
amount of cellular cDNA in 50 ml reactions. These reactions
contained the same constituents as outlined above for RT-PCR
plus 1 mCi32P adCTP 3000 Ci mmol–1 (Amersham, UK) for accu-
rate quantitation. The PCR products were separated on precast 6%
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Figure 1 (A) Representative example of quantitative RT-PCR using primers
specific to GAPDH and MMP-2. The PCR products were separated on a
polyacrylamide gel stained with ethidium bromide and visualized under u.v.
light. PCR reactions from lanes 1–6 and 8–13 contain a constant amount of
cellular cDNA (bottom row) and a 3-fold dilution series of standard competitor
cDNA (top row) for each primer. Lane 7 – molecular weight marker. (B) The
corresponding log-log plot used for quantitation 1666 HM Collins et al 
British Journal of Cancer (2001) 84(12), 1664–1670 © 2001 Cancer Research Campaign
acrylamide gels (Novex, Germany) and visualized using ethidium
bromide (Figure 1A). The fluorescent bands were excised, added
to 400 ml Microscint 40 (Packard, UK) and counts per minute
(cpm) determined using a Packard Top Count. The counts were
normalized for relative dCTP concentration of the standard and
cellular cDNAs. The dilution of standard was plotted on a log-log
scale against the ratio of standard to cellular cDNA (Figure 1B).
The value of the dilution achieved when the ratio of standard to
cellular cDNA is equal to 1 was calculated. The MMPs and TIMPs
were then expressed as a fraction of GAPDH (Glyceraldehyde-3-
phosphate dehydrogenase) in each sample. 
Statistical analysis 
The significance of median gene expression levels between normal
and Dukes’ stage B and C were statistically analysed using the
Mann–Whitney, 2 sample, non-parametric test. This test was also
used to test relationships between the MMPs and their specific
inhibitors. 
Gelatin zymography 
Gelatinolytic activity of secreted proteinases was analysed by
zymography on gels co-polymerized with 0.1% gelatin as described
previously by Brown et al (1990). Conditioned media from the cells
grown in vitro were mixed with equal amounts of SDS sample
buffer (10% (w/v) SDS, 0.5M Tris-HCL (pH 6.8), 10% (v/v) glyc-
erol and 1% Bromophenol blue) (Novex). 10 mm cryostat tissue
sections were mixed with 100 ml SDS buffer. The tissue samples
were allowed to stand for 10 minutes in solution, aspirated through
a fine needle and centrifuged for 1 minute at 13 000 rpm. 25 ml of
sample was loaded onto the gel and electrophoresed. The gelati-
nases that were separated on the gel were renatured for 30 min in
2.5% Triton X-100 at room temperature. This was followed by a 30
min equilibration in a developing buffer containing 50 mM Tris
(pH 7.6), 0.2 M NaCl and 5 mM CaCl2. The gel was incubated for a
further 18 hours in a fresh solution of developing buffer. Gels were
stained with Coomassie Brilliant Blue. Human Recombinant
MMP-2 (72 kDa) kindly donated by British Biotech Ltd (Oxford,
UK) was used as a molecular weight marker. 
Immunohistochemistry 
Frozen sections (4 mm) were cut from the same blocks used
for zymography. Routine histology confirmed the presence of
normal and tumour tissue in the respective specimens.
Immunocytochemistry was performed on all tumour and normal
sections for MMP-2 and MMP-9 using mouse monoclonal anti-
bodies from R&D systems, (Abingdon, UK). The antibodies
specifically bind to both the pro and active forms of each enzyme.
Briefly sections were air dried and fixed in acetone for 10 minutes.
Antibodies were used at 2 mg ml–1 concentration in 10 mM PBS.
The sections were labelled with the Avidin/Biotin complex (ABC)
(Dakopatts, UK) and detected using the DAB detection system
(Sigma, UK). Rabbit serum was used as a negative control and the
specificity of the staining was confirmed by blocking with the
respective antigen. 
RESULTS 
MMP mRNA in vitro 
The 2 colorectal cancer cell lines C170 and C170HM2 were exam-
ined for a range of MMPs when grown in vitro and in vivo. Table 1
1234
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Figure 2 Lane 1 Gelatinase standard displaying the pro form of MMP-9 
(92 kDa) and both the pro and active forms of MMP-2 (72 kDa and 62 kDa).
Lanes 2 and 3 C170HM2 in vivo, Lane 4 C170HM2 in vitro 
Table 1 Non-competitive RT-PCR screen for MMPs, MT-MMPs and TIMPs in cell lines grown in vitro 
Cell line MMP-1 MMP-2 MMP-7 MMP-9  MT-1-MMP MT-2-MMP TIMP-1 TIMP-2 
46BR.IGI + + + + – – + + 
C170 – – + – + + + + 
C170HM2 + – + + + + + + 
Table 2 Quantitative analysis of MMP-2 and MMP-9 mRNA from colorectal cancer cell lines grown in
vitro and in vivo 
C170 C170  C170HM2 C170HM2 C170HM2
(in vitro) (in vivo) (in vitro) (in vivo) (in vivo)
Subcutaneous Subcutaneous Liver invasive
MMP-2 ND 2.76 ´ 10–2 ND ND ND 
MMP-9 ND 2.59 ´ 10–6 2.0 ´ 10–2 1.37 ´ 10–6 7.13 ´ 10–7shows the range of MMPs expressed at the gene level in C170
compared to its metastatic derivative C170HM2. MMP-1 and
MMP-9 were present in the metastatic cell line but absent in the
non-invasive cell line C170. MMP-2 was not detected at the gene
level by in vitro cell monocultures of the colorectal cancer cell
lines. There was expression of almost all the MMPs, including
MMP-2, at the gene level by the fibroblast cell line, MT-1-MMP
and MT-2-MMP were notably absent. 
MMP mRNA in vivo 
Comparisons between the in vitro and the in vivo situation of the
non-invasive cell line C170 revealed low levels of MMPs-1, –2
and –9 in the subcutaneous graft. The main difference between
C170 and C170HM2 was the expression of MMP-2 (albeit low –
2.76 ´ 10–6) in the C170 xenograft, this MMP was not evident from
either the primary or the secondary tumours of C170HM2 (see
Table 2). 
A quantitative analysis of MMP mRNA from the C170HM2
tumours grown at primary (subcutaneous) and secondary sites
(liver) revealed that the same range of MMPs were expressed as
C170HM2 grown in vitro. Levels of C170HM2 MMP-9 mRNA
were however lower in vivo, subcutaneous (1.37 ´ 10–6) and liver
(7.13 ´ 10–7), than in vitro (2 ´ 10–2) (Table 2). Therefore the
expression of this MMP from the murine components of the
tumour were examined to account for any stromal influence on
expression. RT-PCR using mouse-specific primers confirmed
MMP-9 in the mouse stromal component of the xenograft tissue at
both the primary and secondary sites; the liver tissue was negative.
To confirm no cross-reaction with human MMP-9 expression, the
human cell lines grown in vitro were also examined. There was no
expression found in any of the cell lines (results not shown). 
Gelatinase expression in vitro and in vivo 
The gelatinases were examined from cell line supernatants and
xenograft tissue using gelatin zymography. Both gelatinase
proforms were found in the fibroblast supernatant. These enzymes
were not evident in colorectal cancer cell line supernatants,
however the pro-forms of MMP-9 (murine) and MMP-2 along
with active MMP-2 (62 kDa) were present in vivo (Figure 2). 
MMP expression following transwell co-cultivation 
In the transwell co-cultivation system there was de novo expres-
sion of MMP-2 by the colorectal cancer cell lines at the gene and
protein level. Both cell lines also expressed the proform of MMP-
9 in the co-cultivation system (Table 3). Monocultures of the
fibroblast cell line expressed mRNA for MMP-2 and –9 but did
not express MT-1-MMP mRNA, however co-culture with both
colorectal cancer lines induced de novo expression of MT-1-MMP
while retaining expression of MMP-2 and –9. Expression of MT-1-
MMP by the fibroblast cell line did not activate fibroblast or
tumour-derived pro-MMP-2. Colorectal cancer cells co-cultured in
cell–cell contact with fibroblasts expressed non-activated MMP-2
in vitro. 
Non-competitive screen in normal versus tumour 
To look at MMP expression with a fully functional extracellular
matrix, paired tumour and uninvolved mucosa, comprising mostly
of Dukes’B and Dukes’C, moderately differentiated colorectal
adenocarcinomas were analysed, by RT-PCR for the expression of
a wide range of MMPs, their activators and inhibitors. The initial
non-competitive screen revealed that mRNA was present for all
the MMPs and their inhibitors in all of the tumour samples.
However, expression of MMP mRNA was more varied in the
normal samples with a more limited expression pattern (Figure 3):
MMP-1 (37.5%), MMP-2 (50%), MMP-9 (100%), and MMP-7
(100%). MT-1-MMP was expressed in all normal and tumour
samples along with TIMP-1 and TIMP-2, MT-2-MMP was present
Matrix metalloproteinase expression in colon cancer 1667
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Table 3 Cocultivation results 
46BRIGI with  46BRIGI with  C170 with  C170HM2 with 
C170 C170HM2 46BRIGI 46BRIGI 
MMP-2 + + + + 
MMP-9 + + + + 
MT-1-MMP + + + + 
MW
markers
NORMAL
TUMOUR
123456789 1 0 11 12
123456789 1 0 11 12
1353
1078
892
603
310
271
234
194
118
72
1353
1078
892
603
310
271
234
194
118
72
Figure 3 Non-competitive RT-PCR screen of both normal and tumour
colorectal tissue. Lane 1 GAPDH, Lane 2 MMP-1, Lane 3 MMP-2, Lane 4
MMP-9, Lanes 5–7 MMP-3, -10, -11, Lane 8 MMP-7, Lane 9–10 MT-MMP-1, 
-2, Lanes 11–12 TIMP-1, -2 MW marker ØX174 DNA Hae III Digest 
92 kDa
72 kDa
62 kDa
Lanes 123456789 1 0
Figure 4 Lanes 1 and 10 are standard lanes displaying 92 kDa (MMP-9)
and both the pro and active forms of MMP-2 (72 kDa and 62 kDa), Lanes 2–3
and 6–7 are normal colorectal tissue samples while lanes 4–5 and lanes 8–9
are colorectal tumour samples. The tumour samples typically display active
MMP-2 which is absent in normal samples 1668 HM Collins et al 
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in all but one normal sample and all tumour tissue. The amplifica-
tion of GAPDH in all sample tissue confirmed the presence of
intact mRNA in each sample. 
Over-expression of MMP-2 mRNA 
A competitive RT-PCR assay for MMP-2, MMP-9, MT-1-MMP,
TIMP-1 and TIMP-2 positive in the non-competitive screen, was set
up to measure the levels of mRNA present related to the house-
keeping gene GAPDH. The median level of MMP-2 in tumour
tissue (Dukes’B and C) was significantly higher than the median
level in normal tissue (P = 0.0036). The median level in samples
from Dukes’ stage C was significantly higher than Dukes’ stage B
(P = 0.0304) and normal samples (P = 0.0265). The difference
between Dukes’ stage B and normal samples failed to reach signifi-
cance. MT-1-MMP, the specific activator of MMP-2, failed to reach
significance at any stage when the differences in median levels in
tumour were compared to normal tissue. TIMP-2 was expressed in
both normal and tumour tissue, and there was no statistical differ-
ence between the medians of the 2 groups. However, statistical
significance was achieved when the median levels of the ratio
between TIMP-2/MMP-2 in normal tissue was compared to the ratio
of that seen in colorectal tumour tissue (P = 0.0072). 
The median level of MMP-9 in tumour compared to normal
failed to reach significance at any stage. The mRNA levels of
TIMP-1 were generally a lot higher than those found for any of the
MMPs (median levels, normal = 0.265, tumour = 0.347), however
there was no statistical significance in levels found between the
normal and the tumour tissue. The ratio between the inhibitor and
MMP-9 also failed to reach significance. 
Gelatinase expression in human colorectal tissue 
The colorectal tissue analysed by quantitative RT-PCR was also
examined by zymography. In our examination of MMP-2 protein
we found that 7/8 tumours expressed the active form of MMP-2
compared to only one normal sample. This confirmed previous
findings by this group (Parsons et al, 1998) that the active form of
MMP-2 had the tightest correlation with the malignant phenotype
(see Figure 4). 
Immunohistochemistry 
MMP-2 and MMP-9 were analysed at the protein level in
colorectal resection margin normal mucosa and tumour tissue by
immunohistochemistry using monoclonal antibodies and the DAB
detection system. In this study the MMP-2 protein localized to
both the stromal and the epithelial components of tumour tissue
Stromal cells
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A
B
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cells
Normal
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tumour cells
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MMP-2
Figure 5 (A–B). Immunocytochemistry with anti-MMP-2 antibody. 
(A) Colorectal tumour samples displaying immunoreactivity for MMP-2,
predominantly localized to stromal cells. (B) Normal colonic mucosa showing
only occasional positivity in stromal cells. Immunoreactivity is stained as
brown – DAB 
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Figure 6 (A–C). Immunocytochemistry with anti-MMP-9 antibody. (A)
Normal colonic mucosa showing only occasional positivity in stromal cells.
(B–C) Colorectal tumour samples displaying immunoreactivity for MMP-9,
predominantly localized to infiltrating macrophages. Immunoreactivity is
stained as brown – DABMatrix metalloproteinase expression in colon cancer 1669
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(Figure 5A) with only occasional positivity in the normal samples
(Figure 5B). The histology performed with MMP-9 clearly identi-
fies the cellular source as inflammatory cells in both the normal
and the tumour tissue (Figure 6 A–C). 
DISCUSSION 
MMP expression has been linked to the progression of colorectal
cancer but the interactions between MMPs from tumour and host
cells and the processes which activate these enzymes still remains
unclear. Previous research by our group showed significant over-
expression of pro-MMP-9 and pro and active MMP-2 in colorectal
tumours compared to normal mucosa (Parsons et al, 1998). The
present study aimed to establish the range and relative expression
of MMPs produced by stromal cells and their influence on MMPs
produced by colorectal cancer cells at the gene level, both in vitro
(co-cultivation system) and in vivo (subcutaneous xenografts), and
to determine the effect tumour/stromal interactions have on gelati-
nase activation. 
MMP-2 mRNA was expressed by fibroblasts, but not colorectal
cancer lines in vitro, this corresponds with previous studies where
expression was predominantly stromal (Heppner et al, 1996;
Ornstein et al, 1999). The colorectal cancer lines did express
mRNA for the MMP-2 activator, MT-1-MMP, which was absent
from the fibroblast monoculture. De novo expression of fibroblast
MT-1-MMP in transwell co-cultivations indicates that this expres-
sion may be under the control of tumour-derived factors. Polette
et al (1997) showed a similar induction in fibroblasts co-cultured
with breast adenocarcinoma cells and several other studies have
associated increases in MMP-2 expression and activation with
tumour-derived factors (Noel et al, 1994; Biswas et al, 1995).
However, it is the active form of MT-1-MMP and not the gene
expression which is the key to MMP-2 activation. Lehti et al
(1998) demonstrated that fibroblast MT-1-MMP was synthesized
at a reduced rate compared to fibrosarcomas and is immediately
complexed with membrane associated TIMP-2 and MMP-2,
preventing activation, suggesting different post-translational regu-
lation. 
Although fibroblast-derived soluble factors induced the expres-
sion of pro-MMP-2 in tumour cells there was no evidence of acti-
vation when cultured in contact with fibroblasts, activation may
require additional ECM components as the pro and active forms of
MMP-2 were present in vivo. MMP-2 expression may be host in
origin or up-regulated in tumour cells due to host factors.
McDonnell et al (1999) found that although not expressed in vitro,
MMP-2 was present in subcutaneous xenografts with activation
evident in caecal tumours, MMP-2 mRNA in vivo was not exam-
ined. The present study however, revealed that human MMP-2
mRNA was expressed de novo in vivo by a human colorectal
cancer cell line. The MMP-2 protein evident in vivo is likely to be
expressed by both the mouse stroma and human epithelial tissue.
Activation of host MMP-2 may be due to the correct combination
of tumour-derived MT-1-MMP and TIMP-2 along with compo-
nents of the ECM as suggested by the in vitro studies. MMP-2
activation is promoted by culturing cells on fibronection (Stanton
et al, 1998), reinforcing the view that activation may be regulated
by cell–matrix interactions, with the aggregation of b1 integrins
implicated as a key event (Ellerbroek et al, 1999). 
In correlation with earlier findings of over-expression of MMP-
2 protein in colorectal cancer (Parsons et al, 1998), MMP-2
mRNA was significantly increased in Dukes’ C tumours compared
to normal colonic mucosa. MMP-2 was also significantly
increased in Dukes’ C compared to Dukes’B with MMP-2 protein
localized to the stromal component of these tumours. MMP-2 has
been related to tumour progression (D’Errico et al, 1991) with in
situ hybridization localizing expression to the tissue stroma adja-
cent to the invasive front (Poulsom et al, 1992). Increased gelati-
nase expression has also been confirmed in the stromal
components of tumours (Pyke et al, 1993; Zeng and Guillem,
1995). MMP-2 activation was found in 7/8 tumours in the present
study compared to only one normal sample. This increase in
MMP-2 activation in tumours may be due to the significant
increase (P = 0.0072) in MMP-2/TIMP-2 ratio allowing free
MMP-2 to bind to the MT-1-MMP complex in tumour tissue.
Other groups have investigated the significance of this ratio and in
a recent study Masuda and Aoki (1999) found that the ratio of
MMP-2/TIMP-2 was significantly higher in normal colonic tissue
in patients with liver metastasis than in those without metastatic
spread. 
MMP-9, which is a close structural homologue to MMP-2, does
not appear to be similarly expressed or activated. In contrast to
MMP-2, there was no significant increase in MMP-9 mRNA in
tumours compared to normal tissue. This does not correspond to
protein levels discussed in the literature where overexpression
correlated with disease progression (Stetler-Stevenson et al, 1993;
Liabakk et al, 1996). MMP-9 is unique among MMPs in that it has
a nuclear factor-kB promoter recognition site which is inducible
by a range of inflammatory cytokines (Sato et al, 1994). MMP-9
may be up-regulated in adjacent normal tissue due to an infiltra-
tion of inflammatory cells responding to the tumour, MMP-9 was
immunolocalized to inflammatory cells in both normal and tumour
tissue. This correlates well with diseases such as inflammatory
bowel disease which have reported over-expression of MMP-9
(Pender et al, 1997). 
Examination of paired colorectal cancer lines revealed that the
metastatic line expressed MMP-1 and MMP-9 mRNA which were
absent in the parental line in vitro. The presence of MMP-9 mRNA
in the metastatic cells may be due to autocrine stimulation by
growth factors or cytokines known to induce MMPs (Birkedal-
Hansen et al, 1993). Hyuga et al (1994) found that an autocrine
factor enhanced the expression and secretion of MMP-9 in serum-
free media conditioned with murine metastatic colon carcinoma
cells which was not repeated with cells of low metastatic potential.
Further work by the same group linked this enhancement to
TGFb1 (Shimizu et al, 1996). We have demonstrated paracrine
stimulation of MMP-9 in co-cultivation studies with an increase in
protein from C170HM2 cells, along with de novo mRNA and
protein expression from C170 cells. Lengyel et al (1995) has
shown that paracrine factors secreted by fibroblasts induced
MMP-9 in a squamous cell carcinoma line. This paracrine stimula-
tion in vitro was also reflected in vivo. The liver metastatic
tumours grown in vivo expressed pro-MMP-9 which was expected
as this line expressed human MMP-9 mRNA in vitro, however,
MMP-9 was now also expressed by C170 tumours. Examination
of xenograft tissue using mouse-specific primers revealed that the
host tissue was also responsible for producing MMP-9. When
MMP-9 gene expression was quantified in the C170HM2 cell line
both in vitro and in vivo there was a notable decrease in human
MMP-9 in the xenograft. Analysis of in vivo tumours via zymog-
raphy revealed that pro-MMP-9 was ~103 kDa known to be the
murine form (Masure et al, 1993), thus MMP-9 protein is of
mouse stromal origin, despite the epithelial cells expressing the1670 HM Collins et al 
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gene. McDonnell et al (1999) found that MMP-9 in subcutaneous
and caecal tumours was host derived, confirmed by RT-PCR and
in situ hybridization, where the signal was stromal and found
predominantly at the tumour/stromal interface. In a study by
Segain et al (1996), it was demonstrated that fibroblast MMP-9
was induced by direct cell–cell contact with cell lines derived from
primary colorectal tumours and that cell surface molecules may
trigger this signalling pathway. 
In conclusion we have demonstrated that MMP expression is
influenced by autocrine and paracrine stimulation and that MMP-2
activation requires co-operation between epithelial and stromal
cells as well as ECM components. We have illustrated the over-
expression of MMP-2 mRNA in colorectal cancer compared to
normal mucosa and indicated that it is the ratio of this enzyme in
relation to its activator and inhibitor which is important in deter-
mining the overall degradative process. Specific inhibitors which
target MMP-2 activity (or components of the ECM which facili-
tate this activation) may be of therapeutic benefit to patients with
colorectal cancer. 
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